We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > episodic migraine

News List

Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine worldpharmanews
July 05, 2018
Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in epis worldpharmanews
January 23, 2018
The study met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50% reduction from baseline in their monthly migraine days as compared to placebo.